Galapagos (GLPG) investor relations material

Executive summary

• 2025 marked a strategic transformation, shifting focus from cell therapy to business development and long-term value creation, supported by a new leadership team and board with deep M&A and biopharma experience.

• Collaboration with Gilead remains a key strategic advantage, providing deal flexibility and supporting capital allocation.

• Leaner organization targeted, with 35–40 employees by end of 2026, maintaining key locations in Belgium and the US.

Financial highlights

• Year-end 2025 cash and financial investments totaled €3.0 billion, with a decrease from €3,317.8 million at end-2024.

• Total net revenues for 2025 were €1,112.2 million, up 304% year-over-year, mainly due to full recognition of €1,069 million deferred income from Gilead collaboration.

• Operating profit from continuing operations was €295.1 million in 2025, reversing a loss of €188.3 million in 2024.

• Net profit for 2025 was €320.9 million, up from €74.1 million in 2024.

• R&D expenses rose 37% to €459.4 million, driven by cell therapy wind-down and early termination costs.

Outlook and guidance

• Cell therapy wind down expected to be substantially completed by end of Q3 2026, with one-time restructuring cash impact of €125–175 million in 2026.

• Additional €35–40 million in cash costs for final restructuring implementation in 2026.

• Up to €40 million expected for ongoing TYK2 program and phase two clinical trials in 2026.

• Anticipates being cash flow neutral to positive by year-end 2026, with year-end cash forecasted between €2.775 and €2.85 billion, excluding major business development or currency effects.